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A total of 74 clinical isolates of Branhamella catarrhalis were characterized with respect to their ampicillin,
amoxicillin-clavulanate, cephalothin, cefaclor, erythromycin, tetracycline, chloramphenicol, and trimetho-
prim-sulfamethoxazole MICs and zones of inhibition. Disk diffusion tests were performed according to the
guidelines of the National Committee for Clinical Laboratory Standards with two different media (Mueller-
Hinton agar and chocolate Mueller-Hinton agar) and plates incubated under two atmospheric conditions
(ambient air and 5 to 7% CO2). Optimum disk diffusion test results were obtained with Mueller-Hinton agar
plates incubated in ambient air with all eight antimicrobial agents. On the basis of comparisons of MICs versus
zones of inhibition, the following zone diameter interpretive criteria were defined for testing B. catarrhalis with
disks containing 10 ,ug of ampicillin: .38 mm, susceptible; 20 to 37 mm, moderately susceptible; -19 mm,
resistant. The respective MIC correlates were s0.06, 0.125 to 0.5, and .1.0 ,ug/ml. Because of the absence of
frankly resistant test organisms, it was not possible to make definitive recommendations pertaining to disk
diffusion tests with amoxicillin-clavulanate, cephalothin, cefaclor, erythromycin, tetracycline, chlorampheni-
col, and trimethoprim-sulfamethoxazole. Evidence is presented, however, which suggests that the current
National Committee for Clinical Laboratory Standards disk diffusion interpretive criteria for nonfastidious
bacteria can be applied to B. catarrhalis, at least as they pertain to the susceptible category with cephalothin,
amoxicillin-clavulanate, erythromycin, tetracycline, chloramphenicol, and trimethoprim-sulfamethoxazole.
With cefaclor, a zone diameter of ;21 mm was determined to adequately define the susceptible category.
Branhamella catarrhalis is now recognized as an impor-
tant cause of acute otitis media, maxillary sinusitis, and
bronchopulmonary infections in humans (4). Most clinical
isolates of B. catarrhalis produce P-lactamase (1, 2, 6, 13,
15, 21). Infections caused by P-lactamase-producing strains
have been reported to be refractory to therapy with ,B-lactam
antimicrobial agents such as penicillin, ampicillin, and
amoxicillin (17, 21, 24). Interestingly, however, there have
been reports of patients with infections due to strains of B.
catarrhalis which produced P-lactamase who have re-
sponded to treatment with these agents (5, 7, 12). Further-
more, several in vitro susceptibility studies have described
P-lactamase-positive strains of B. catarrhalis with penicillin
and ampicillin MICs as low as 0.1 to 0.5 ,ug/ml (3, 22, 23). It
is possible, therefore, that the presence or absence of
P-lactamase activity is not necessarily predictive of thera-
peutic outcome in all patients with B. catarrhalis infections
who are treated with penicillin-class antimicrobial agents. If
this were so, then some direct assay of in vitro activity such
as a disk diffusion or broth-agar dilution test would be
necessary to predict the therapeutic efficacy of these agents.
In addition, there have now been reports in Sweden, The
Netherlands, and Japan of resistance to alternative agents
such as trimethoprim-sulfamethoxazole, cefaclor, erythro-
mycin, and tetracycline among clinical isolates of B. catar-
rhalis (9-11, 14, 20). Although resistance to these antimicro-
bial agents has not been reported in the United States, it is
possible that resistance will become a problem. If this
occurs, then there will exist a need for in vitro susceptibility
tests which effectively predict the in vivo activities of these
compounds as well.
* Corresponding author.
Heretofore, disk diffusion susceptibility testing of B.
catarrhalis has not been systematically evaluated, at least
with respect to antimicrobial agents other than penicillin and
ampicillin. It was the intent of the current investigation to
examine a standardized disk diffusion susceptibility proce-
dure as a means for assessing the in vitro activities of
ampicillin, amoxicillin-clavulanate, cephalothin, cefaclor,
erythromycin, tetracycline, chloramphenicol, and trimetho-
prim-sulfamethoxazole versus clinical isolates of B. catar-
rhalis.
MATERIALS AND METHODS
Organisms. Of 74 recently obtained clinical isolates of B.
catarrhalis examined, 13 were from patients seen at the
University of Massachusetts Medical Center, Worcester; 20
were provided by S. L. Berk, Veterans Administration
Medical Center, Johnson City, Tenn.; 40 were the gift of
R. J. Wallace, University of Texas Health Science Center,
Tyler; and 1 was received from A. von Graevenitz, Univer-
sity of Zurich Institute of Medical Microbiology, Zurich,
Switzerland. Of these 74 strains, 58 produced 3-lactamase
when tested in a conventional nitrocefin assay (19), and 16
lacked P-lactamase activity.
All strains were maintained as stock cultures at -70°C in
2% skim milk until just before testing, Stock cultures were
thawed, and samples were inoculated onto plates containing
5% sheep blood agar (Scott Laboratories, Inc., Fiskeville,
R.I.). Following incubation for 20 to 24 h at 35°C in ambient
atmospheric air, isolated colonies were subcultured to a
second sheep blood agar plate, which was incubated under
identical conditions. Growth from this plate was used to
prepare inocula for all subsequent studies.
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TABLE 1. Comparisons of zone diameters obtained with 74 strains of B. catarrhalis tested with a standardized disk diffusion method
by using two different test media and two different atmospheres of incubation
Avg (minimum/maximum) difference (mm) between zones of inhibition obtained under
the following conditions:
Antimicrobial agent
MHA in CO, vs CHOC-MHA in CO, CHOC-MHA in air CHOC-MHA in CO2
MHA in air vs CHOC-MHA in air vs MHA in air vs MHA in CO2
Ampicillin + 1.8 (-2/+ 8) + 1.3 (-2/+4) -0.4 (-4/+ 1) -0.9 (-51+ 2)
Amoxicillin-clavulanate + 2.9 (-3/+ 10) +0.6 (-4/+ 5) -1.5 (-4/0) -4.1 (-9/-i)
Cephalothin + 0.3 (-4/+ 7) + 0.1 (-4/+ 5) -0.1 (-3/+ 1) -0.4 (-6/+4)
Cefaclor +5.4 (0/+13) +3.2 (0/+8) -1.4 (-4/+1) -3.6 (-9/-2)
Erythromycin +1.2 (-3/+6) +0.6 (-3/+4) -1.0 (-3/+2) -1.7 (-5/+1)
Tetracycline + 12.2 (+ 6/+ 17) +9.9 (+ 8/+ 14) -7.2 (-10/-4) -7.9 (-14/+ 2)
Chloramphenicol +6.6 (+3/+ 13) +2.9 (-1/+8) -1.9 (-6/+ 1) -5.6 (-11/-1)
Trimethoprim-sulfamethoxazole + 5.9 (+ 1/+ 12) + 5.1 (+ 2/+ 11) -1.0 (-5/+ 2) -1.7 (-6/+ 1)
Determination of MICs. MICs were determined by a tube
broth macrodilution technique which used cation-supple-
mented Mueller-Hinton broth (pH 7.2; final volume, 2.0 ml)
and an inoculum of 1 x 105 to 2 x 105 CFU/ml (final
concentration). Mueller-Hinton broth was obtained from
Scott Laboratories. The following antimicrobial agents, ob-
tained as reagent grade powders from the manufacturers,
were examined in twofold concentration increments ranging
from 0.004 to 256 pug/ml: ampicillin (Bristol Laboratories,
Syracuse, N.Y.), amoxicillin-clavulanate (Beecham Labora-
tories, Bristol, Tenn.), cephalothin (Eli Lilly & Co., India-
napolis, Ind.), cefaclor (Eli Lilly), erythromycin (Bristol),
tetracycline (Parke, Davis & Co., Morris Plains, N.J.),
chloramphenicol (Parke, Davis), and trimethoprim-sulfa-
methoxazole (Roche Diagnostics, Div. Hofmann-La Roche
Inc., Nutley, N.J.). Amoxicillin-clavulanate was tested at a
constant ratio of 2 parts amoxicillin to 1 part clavulanate;
trimethoprim-sulfamethoxazole was tested at a constant
ratio of 1 part trimethoprim to 19 parts sulfamethoxazole.
Tubes were incubated at 35°C in air for 20 h and examined
macroscopically for turbidity. The MIC was defined as the
lowest concentration which yielded no macroscopic evi-
dence of turbidity. All determinations were made in dupli-
cate, and the results were averaged to obtain an estimate of
the MIC for a given organism-antimicrobial agent combina-
tion. In cases in which duplicate MICs varied by only one
twofold concentration, the lower value was assigned as the
MIC for the organism. In no case were duplicate MIC
determinations found to vary by more than fourfold.
Disk diffusion susceptibility procedure. A standardized disk
diffusion susceptibility test was performed precisely as de-
scribed by the National Committee for Clinical Laboratory
Standards (16). Filter disks (BBL Microbiology Systems,
Cockeysville, Md.) contained- the following antimicrobial
agents in the following amounts: ampicillin (10 ,ug), amoxicil-
lin-clavulanate (20 or 10 ,ug), cephalothin (30 ,ug), erythro-
mycin (15 ,ug), tetracycline (30 ,ug), chloramphenicol (30 ,ug),
and trimethoprim-sulfamethoxazole (1.25 or 23.75 ,ug).
Cefaclor disks (30 ,ug) were obtained from Eli Lilly. Two
different media were evaluated: Mueller-Hinton agar (MHA;
pH 7.2) and MHA containing a 1.0% IsoVitaleX supplement
(BBL) and 1.0% bovine hemoglobin (CHOC-MHA; pH 7.2).
MHA was obtained from Scott Laboratories. Following
inoculation and application of antimicrobial disks, plates
were incubated for 16 to 18 h at 35°C in each of two
atmospheres: ambient room air and 5 to 7% CO2. Zones of
inhibition were measured to the nearest millimeter with a
caliper. All determinations were done in duplicate, and the
results were averaged. In no case was a variation of >4 mm
observed between the results of duplicate determinations.
RESULTS
The effects of medium composition and atmosphere of
incubation on zones of inhibition obtained in disk diffusion
susceptibility tests with B. catarrhalis are shown in Table 1.
When test plates were incubated in both ambient atmo-
spheric air and 5 to 7% CO2, zones of inhibition were smaller
on CHOC-MHA than on MHA. These differences were most
conspicuous with selected antimicrobial agents, i.e.,
amoxicillin-clavulanate, cefaclor, tetracycline, and chloram-
phenicol. The atmosphere of incubation also seemed to
influence zone sizes. Irrespective of the medium used, zones
of inhibition obtained with disk diffusion plates incubated in
5 to 7% CO2 were larger than those obtained with plates
incubated in ambient air. Again, the differences were most
pronounced with certain agents, in particular, cefaclor,
tetracycline, chloramphenicol, and trimethoprim-sulfameth-
oxazole. The results of disk diffusion susceptibility tests
performed with MHA plates incubated in ambient air were
used for all further data analysis.
The relationship between MICs and zones of inhibition
obtained with individual isolates of B. catarrhalis versus
eight antimicrobial agents is depicted in Fig. 1 (ampicillin,
cephalothin, cefaclor, and amoxicillin-clavulanate) and 2
(erythromycin, tetracycline, chloramphenicol, and trimeth-
oprim-sulfamethoxazole). An inverse relationship between
MICs and zones of inhibition was apparent with ampicillin
and cephalothin and to some extent with cefaclor and
amoxicillin-clavulanate. With erythromycin, tetracycline,
chloramphenicol, and trimethoprim-sulfamethoxazole-, there
was no evident relationship between MICs and zones of
inhibition; i.e., different strains with the same MICs had
widely varying zone sizes.
It should be emphasized that, with the exception of
ampicillin, the range of MICs for the 74 test strains was
relatively narrow. Furthermore, on the basis of MIC deter-
minations, none of the strains of B. catarrhalis examined in
this study would have been characterized as frankly resistant
to agents other than ampicillin.
,-Lactamase production appeared to influence MICs and
zones of inhibition with three antimicrobial agents: ampicil-
lin, cephalothin, and cefaclor (Table 2). Specifically,- ,B-
lactamase-negative strains of B. catarrhalis were inhibited
by significantly lower concentrations of these three antimi-
crobial agents and had significantly larger zone sizes than did
,-lactamase-producing strains. With amoxicillin-clavula-
nate, erythromycin, tetracycline, chloramphenicol, and tri-
methoprim-sulfamethoxazole, the MICs and zone sizes for
,3-lactamase-producing strains were essentially equivalent to
those obtained with strains which lacked r-lactamase.
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FIG. 1. Comparison of ampicillin (A), amoxicillin-clavulanate (B), cephalothin (C), and cefaclor (D) MICs and zones of inhibition for 74
strains of B. catarrhalis. Amoxicillin-clavulanate was tested at a constant ratio of 2 parts amoxicillin to 1 part clavulanate; the concentration
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FIG. 2. Comparison of erythromycin (A), tetracycline (B), chloranlphenicol (C), and trimethoprim-sulfamethoxazole (D) MICs and zones
of inhibition for 74 strains of B. catarrhalis. Trimethoprim-sulfamethoxazole was tested at a constant ratio of 1 part trimethoprim to 19 parts
sulfamethoxazole; the concentration listed is that of trimethoprim. Symbols: 0, P-lactamase-positive strains (n = 58); A, 3-lactamase-














































TABLE 2. Comparison of MICs and zones of inhibition obtained with ,B-lactamase-positive strains of B. catarrhalis versus
strains which lacked 13-lactamasel
Geometric mean MIC (,ug/ml) Avg zone diam (mm)
Antimicrobial agent ,B-Lactamase 1-Lactamase ,B-Lactamase 1-Lactamase
positive negative positive negative
Ampicillin 0.84 0.03 19.6 43.3
Amoxicillin-clavulanate 0.06 0.02 39.9 43.1
Cephalothin 4.07 0.78 19.2 36.3
Cefaclor 1.0 0.25 25.6 37.6
Erythromycin 0.10 0.10 33.0 31.2
Tetracycline 0.33 0.36 30.2 29.0
Chloramphenicol 0.49 0.48 37.6 36.6
Trimethoprim-sulfamethoxazole 0.12 0.11 27.8 26.4
a MICs were determined with a tube broth macrodilution method. Zones of inhibition were determined by a standardized disk diffusion method which used
Mueller-Hinton agar plates incubated in ambient air. We examined 58 l3-lactamase-positive and 16 ,-lactamase-negative strains.
DISCUSSION
In a recent communication which described the results of
a nationwide laboratory proficiency survey pertaining to disk
diffusion susceptibility testing of B. catarrhalis, significant
variation was noted among results obtained from numerous
participating laboratories (8). Since there existed little uni-
formity as to test method or interpretive criteria, this vari-
ability of test results was not unexpected. Indeed, the
authors of this report emphasized the need for a systematic
investigation of disk diffusion susceptibility testing of B.
catarrhalis with the aim of clearly defining an optimum test
method and suitable interpretive criteria. Recently, there
have been two published studies which have addressed this
issue (13, 23). In one study, however, only 25 strains of B.
catarrhalis were examined, and 15 of these were not clinical
isolates (23). In the second study, which incorporated a large
number of clinically significant isolates of B. catarrhalis, the
results of disk diffusion susceptibility tests were compared
as to the presence or absence of ,B-lactamase production but
not to quantitative estimates of antimicrobial activity (13).
Recognizing the emerging significance of B. catarrhalis as a
human pathogen (4) and the need for acceptable susceptibil-
ity test criteria (8), we conducted the current study in an
attempt to define suitable conditions for performing disk
diffusion tests with this organism and to define interpretive
criteria.
The results of this investigation clearly indicate that me-
dium composition and atmosphere of incubation influence
the results of disk diffusion susceptibility tests with B.
catarrhalis. With respect to medium composition, use of
CHOC-MHA resulted in zones of inhibition that were, in
general, smaller than those obtained with MHA. Incubation
of test plates in an atmosphere of 5 to 7% CO2 yielded zone
sizes larger than those observed with plates incubated in
ambient air. Because the current standard method for disk
diffusion susceptibility testing of nonfastidious bacteria ad-
vocates use ofMHA with incubation of test plates in air (16),
and since all of the strains of B. catarrhalis examined in this
study were readily propagated under these conditions, we
advocate that disk diffusion susceptibility tests of B. catar-
rhalis be performed on MHA with plates incubated in
ambient atmospheric air.
A recent report which characterized 231 clinical isolates of
B. catarrhalis described 26 strains (11%) which failed to
grow adequately on MHA in ambient air (13). As stated
above, this problem was not encountered among the 74
strains characterized in the current study. Furthermore, we
examined approximately 100 additional clinical isolates of B.
catarrhalis and did not identify a single strain which failed to
grow adequately on MHA in ambient air at 35°C after
incubation for 18 h.
The results of the current investigation seem to provide a
basis for making definitive recommendations regarding inter-
pretive criteria to be applied when testing B. catarrhalis with
10-,ug ampicillin disks. We propose that organisms for which
MICs are -0.06 ,ug/ml be considered susceptible, those for
which MICs are 0.125 to 0.5 ,ug/ml be identified as moder-
ately susceptible, and those for which MICs are -1.0 ,ug/ml
be viewed as resistant. The zone size interpretive criteria
would be >38, 20 to 37, and '19 mm, respectively. These
recommnendations are based on definitions of susceptibility
categories based on MIC ranges with extrapolation to zones
of inhibition on the basis of linear regression analysis by the
least-squares method. This approach seems to be justified,
since a high degree of correlation was noted between MICs
and zone diameters (i.e., r = 0.864). On the basis of the
results of the current study, use of the zone size interpretive
criteria recommended above would have resulted in the
classification of one moderately susceptible (MIC, 0.125
,ug/ml) strain as falsely susceptible, one susceptible (MIC,
0.03 ,ug/ml) strain as falsely moderately susceptible, and one
moderately susceptible (MIC, 0.25 p.g/ml) strain as falsely
resistant.
Traditionally, ,B-lactamase production is construed as in-
dicating penicillin and ampicillin resistance, irrespective of
MICs or zones of inhibition. One consequence of using the
interpretive criteria recommended above when performing
ampicillin disk diffusion susceptibility tests with B. catar-
rhalis is that a small percentage of ,-lactamase-producing
strains is classified as moderately susceptible rather than
resistant. We feel that this is justified for the following
reasons. With respect to predicting therapeutic efficacy of
ampicillin when used to treat B. catarrhalis infections, as
stated in the introduction, MICs may be of greater predictive
value than ,B-lactamase determinations insofar as not all
infections due to ,-lactamase-prodtucing strains seem to be
refractory to therapy with ampicillin. Further, organisms for
which determination of ,-lactamase production necessarily
translates into clinical resistance to penicillin and ampicillin
(i.e., Staphylococcus aureus, Haemophilus influenzae, and
Neisseria gonorrhoeae) are not representative of B. catar-
rhalis. B. catarrhalis ,B-lactamase is distinctly different from
the ,-lactamases produced by these organisms. Finally, it
should be recognized that a great deal is still to be learned
about the role of B. catarrhalis as a human pathogen. When
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we have a better understanding of this organism as a cause of
human infection, it may be necessary to revise susceptibility
test criteria.
It is difficult to make definitive recommendations regard-
ing disk diffusion interpretive criteria for the other antimi-
crobial agents examined in this study, i.e., cephalothin,
cefaclor, amoxicillin-clavulanate, erythromycin, tetracy-
cline, chloramphenicol, and trimethoprim-sulfamethoxa-
zole. First of all, strains of B. catarrhalis with frank resis-
tance to these antimicrobial agents were not found.
Secondly, with the exception of cephalothin and perhaps
cefaclor and amoxicillin-clavulanate, an inverse relationship
between MICs and zones of inhibition was not apparent.
Despite these shortcomings, however, it may be possible to
make certain assertions regarding B. catarrhalis disk diffu-
sion susceptibility tests with these antimicrobial agents.
Specifically, it appears as though the zone diameter inter-
pretive standards used to define the susceptible category in
the National Committee for Clinical Laboratory Standards
guidelines for disk diffusion testing of nonfastidious bacteria
can be applied to B. catarrhalis when tested versus amoxicil-
lin-clavulanate, erythromycin, tetracycline, chlorampheni-
col, and trimethoprim-sulfamethoxazole (16). With respect
to cephalothin disk diffusion testing of B. catarrhalis, the
National Committee for Clinical Laboratory Standards zone
size standards for both the susceptible and intermediate
categories are acceptable.
Interpretation of the results of disk diffusion susceptibility
testing of B. catarrhalis with cefaclor remains problematic.
The National Committee for Clinical Laboratory Standards
guidelines promulgate cephalothin as the class agent for
certain related cephalosporins, including cefaclor (18). In the
case of B. catarrhalis, the results of the current investigation
clearly indicate that cefaclor and cephalothin differ consid-
erably in their abilities to inhibit the growth of this organism,
i.e., cefaclor possesses significantly greater activity than
does cephalothin. Therefore, cephalothin cannot be used as
a class agent for predicting the activity of cefaclor with B.
catarrhalis.
The manufacturer of the cefaclor disks used in this study
suggests use of the following zone diameter interpretive
criteria: .21 mm, susceptible; 17 to 20 mm, intermediate;
<16 mm, resistant. In the current investigation, all 74 study
strains were susceptible to cefaclor on the basis of MICs,
and zones of inhibition were -21 mm for all but one strain.
The single exception was a strain for which the zone size was
20 mm. It can be inferred from these observations that the
manufacturer recommended criteria for defining strains as
susceptible to cefaclor probably apply to B. catarrhalis.
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